ASX - By Stock
|
ILA |
Re:
Ann: Completion of Galidesivir transaction
|
|
lilypily
|
45 |
9.9K |
13 |
08/08/25 |
08/08/25 |
ASX - By Stock
|
45
|
9.9K
|
13
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Portfolio expansion achieved with acquisition of Galidesivir
|
|
lilypily
|
118 |
29K |
4 |
09/07/25 |
09/07/25 |
ASX - By Stock
|
118
|
29K
|
4
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Portfolio expansion achieved with acquisition of Galidesivir
|
|
lilypily
|
118 |
29K |
18 |
09/07/25 |
09/07/25 |
ASX - By Stock
|
118
|
29K
|
18
|
|
ASX - By Stock
|
COV |
Re:
Ann: Corporate Presentation
|
|
lilypily
|
10 |
3.3K |
4 |
09/07/25 |
09/07/25 |
ASX - By Stock
|
10
|
3.3K
|
4
|
|
ASX - By Stock
|
COV |
Re:
Ann: Corporate Presentation
|
|
lilypily
|
10 |
3.3K |
9 |
25/06/25 |
25/06/25 |
ASX - By Stock
|
10
|
3.3K
|
9
|
|
ASX - By Stock
|
COV |
Re:
Ann: Corporate Presentation
|
|
lilypily
|
10 |
3.3K |
2 |
12/06/25 |
12/06/25 |
ASX - By Stock
|
10
|
3.3K
|
2
|
|
ASX - By Stock
|
COV |
Re:
Ann: CLEO to Fast Track Development of Ovarian Cancer Test
|
|
lilypily
|
12 |
4.6K |
2 |
02/06/25 |
02/06/25 |
ASX - By Stock
|
12
|
4.6K
|
2
|
|
ASX - By Stock
|
COV |
Re:
Ann: CLEO to Fast Track Development of Ovarian Cancer Test
|
|
lilypily
|
12 |
4.6K |
3 |
02/06/25 |
02/06/25 |
ASX - By Stock
|
12
|
4.6K
|
3
|
|
ASX - By Stock
|
ILA |
Re:
ILA Industry news
|
|
lilypily
|
31 |
11K |
8 |
24/02/25 |
24/02/25 |
ASX - By Stock
|
31
|
11K
|
8
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
lilypily
|
62 |
34K |
8 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
62
|
34K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
lilypily
|
1.6K |
833K |
28 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
1.6K
|
833K
|
28
|
|
ASX - By Stock
|
COV |
Re:
Ann: Completion of First Triage Test Clinical Validation Study
|
|
lilypily
|
2 |
2.4K |
6 |
07/11/23 |
07/11/23 |
ASX - By Stock
|
2
|
2.4K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline
|
|
lilypily
|
44 |
17K |
7 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
44
|
17K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline
|
|
lilypily
|
44 |
17K |
11 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
44
|
17K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
lilypily
|
356 |
142K |
4 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
356
|
142K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study
|
|
lilypily
|
286 |
98K |
3 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
286
|
98K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study
|
|
lilypily
|
286 |
98K |
19 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
286
|
98K
|
19
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
lilypily
|
111 |
47K |
10 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
111
|
47K
|
10
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
lilypily
|
59 |
19K |
7 |
18/06/20 |
18/06/20 |
ASX - By Stock
|
59
|
19K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren to capture substantially greater value after Phase 3
|
|
lilypily
|
96 |
40K |
5 |
05/06/20 |
05/06/20 |
ASX - By Stock
|
96
|
40K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren announces changes to leadership team
|
|
lilypily
|
55 |
22K |
0 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
55
|
22K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren announces changes to leadership team
|
|
lilypily
|
55 |
22K |
2 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
55
|
22K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren announces changes to leadership team
|
|
lilypily
|
55 |
22K |
9 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
55
|
22K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
lilypily
|
85 |
37K |
5 |
20/03/20 |
20/03/20 |
ASX - By Stock
|
85
|
37K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
lilypily
|
85 |
37K |
4 |
20/03/20 |
20/03/20 |
ASX - By Stock
|
85
|
37K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
lilypily
|
85 |
37K |
0 |
20/03/20 |
20/03/20 |
ASX - By Stock
|
85
|
37K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren to capture substantially greater value after Phase 3
|
|
lilypily
|
96 |
40K |
3 |
17/03/20 |
17/03/20 |
ASX - By Stock
|
96
|
40K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Additional information
|
|
lilypily
|
20 |
10K |
1 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
20
|
10K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Additional information
|
|
lilypily
|
20 |
10K |
3 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
20
|
10K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Additional information
|
|
lilypily
|
20 |
10K |
0 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
20
|
10K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Appoints New DMX-200 Medical Advisory Board
|
|
lilypily
|
10 |
5.0K |
5 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
10
|
5.0K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Appoints New DMX-200 Medical Advisory Board
|
|
lilypily
|
10 |
5.0K |
7 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
10
|
5.0K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Compelling results for 2591 dose ranging study in PMS model
|
|
lilypily
|
44 |
23K |
0 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
44
|
23K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Compelling results for 2591 dose ranging study in PMS model
|
|
lilypily
|
44 |
23K |
7 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
44
|
23K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Compelling results for 2591 dose ranging study in PMS model
|
|
lilypily
|
44 |
23K |
24 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
44
|
23K
|
24
|
|
ASX - By Stock
|
NEU |
Re:
Unbelievable....
|
|
lilypily
|
31 |
15K |
4 |
05/03/20 |
05/03/20 |
ASX - By Stock
|
31
|
15K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Commentary on potential benefit to Neuren of RPD designation
|
|
lilypily
|
25 |
9.8K |
1 |
04/03/20 |
04/03/20 |
ASX - By Stock
|
25
|
9.8K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 5 Orphan Drug programs and Rett in Phase 3 funded by partner
|
|
lilypily
|
49 |
1.6M |
20 |
03/03/20 |
03/03/20 |
ASX - By Stock
|
49
|
1.6M
|
20
|
|
ASX - By Stock
|
DXB |
Re:
Ann: DMX-200 Treatment Continued Under TGA Special Access Scheme
|
|
lilypily
|
61 |
28K |
10 |
03/03/20 |
03/03/20 |
ASX - By Stock
|
61
|
28K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Appendix 4E and 2019 full year accounts
|
|
lilypily
|
95 |
483K |
2 |
28/02/20 |
28/02/20 |
ASX - By Stock
|
95
|
483K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
How long?.
|
|
lilypily
|
143 |
114K |
7 |
18/02/20 |
18/02/20 |
ASX - By Stock
|
143
|
114K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
How long?.
|
|
lilypily
|
143 |
114K |
9 |
18/02/20 |
18/02/20 |
ASX - By Stock
|
143
|
114K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
How long?.
|
|
lilypily
|
143 |
114K |
21 |
14/02/20 |
14/02/20 |
ASX - By Stock
|
143
|
114K
|
21
|
|
ASX - By Stock
|
NEU |
Re:
Trading
|
|
lilypily
|
467 |
2.3M |
0 |
08/02/20 |
08/02/20 |
ASX - By Stock
|
467
|
2.3M
|
0
|
|
ASX - By Stock
|
NEU |
Re:
NEUREN PRIMED
|
|
lilypily
|
21 |
22K |
5 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
21
|
22K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
NEUREN PRIMED
|
|
lilypily
|
21 |
22K |
12 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
21
|
22K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
NEUREN PRIMED
|
|
lilypily
|
21 |
22K |
23 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
21
|
22K
|
23
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2019 year-end update and 2020 outlook
|
|
lilypily
|
171 |
121K |
7 |
16/01/20 |
16/01/20 |
ASX - By Stock
|
171
|
121K
|
7
|
|
ASX - By Stock
|
DXB Biotech |
Re:
Taylor's Initiation
|
|
lilypily
|
67 |
34K |
5 |
12/12/19 |
12/12/19 |
ASX - By Stock
|
67
|
34K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2019 year-end update and 2020 outlook
|
|
lilypily
|
171 |
121K |
25 |
12/12/19 |
12/12/19 |
ASX - By Stock
|
171
|
121K
|
25
|
|